Navigation Links
Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
Date:12/20/2013

lied to.  These opportunities most notably include Binge Eating Disorder, Bulimia Nervosa, and amphetamine and cocaine addiction.

Over the past year, there have been some major advancements throughout these markets.  On top of our compelling Phase II data we reported in August 2012, which demonstrated the efficacy and safety of intra-nasal naloxone for Binge Eating Disorder, the American Psychiatric Association (APA) officially added Binge Eating Disorder to the DSM-5 manual in May 2013. DSM-5 is used by clinicians and researchers to diagnose and classify mental disorders in order to improve diagnoses, treatment and research. This manual is the product of more than 10 years of effort by hundreds of international experts in all aspects of mental health.  This elevated status places an even greater importance on the clinical work we are doing as it is now an officially recognized disease state by the APA.  Over the past few months, we have continued our preparation work for our next anticipated study to be conducted in the U.S.

For Bulimia Nervosa, we expect to commence a Phase II in 2014 in partnership with King's College London.  It is important to note that because we are using an approved drug in a unique, specialized formulation, our clinical trials typically are much shorter and cost efficient than a regular biotech clinical trial.  This potentially allows us to receive regulatory approval in a faster manner and shortens our time to commercialization.

Operationally, we continue to be meticulous in managing our cash position and we are utilizing all of our resources as efficiently as possible.  Through meaningful partnerships, high level collaboration and diligent execution, we anticipate a very exciting year ahead.

In summary, 2013 was a year of great progress, which would not have been possible without the continued support of our loyal shareholders.  We look forward to continue making great s
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
2. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
3. Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
4. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
5. BiOptix Continues Support of Antibody Engineering & Therapeutics Research
6. NKT Therapeutics Identifies Novel anti-iNKT Antibodies for Depleting or Activating iNKT Cells
7. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
8. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
9. Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
10. Scientists develop way to successfully give nanoparticle therapeutics orally
11. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 19, 2011 , , • ... MS drug with neuroprotective effects that does not cause,immunosuppression. ... the first,to be administered orally, whereas the few treatments ... significant side effects. • NeuroAdvan, the ...
... Mosquitoes die soon after a blood meal if certain ... at the University of Arizona has discovered. The ... the worldwide effort to curb mosquito-borne diseases like dengue ... blocked a cellular process known as vesicle transport, on ...
... dots made from cadmium and selenium degrade in soil, ... a University at Buffalo study has found. The ... Science and Technology , demonstrates the importance of learning ... -- interact with the environment after disposal, said Diana ...
Cached Biology Technology:Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Making blood-sucking deadly for mosquitoes 2Making blood-sucking deadly for mosquitoes 3Making blood-sucking deadly for mosquitoes 4Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 2Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 3
(Date:4/15/2014)... fuel cell systems soon could be powering the forklifts ... costs and with faster refueling times than ever before, ... Hawaii Hydrogen Carriers (HHC). , The goal of the ... that can refuel at low pressure four to five ... forklift, giving hydrogen a competitive advantage over batteries for ...
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2
... birthday, according to new infant mortality statistics for 2003 ... , The infant mortality rates showed no significant improvement ... time since 1958. , In 2003, the infant ... births, which was statistically unchanged from the 2002 rate ...
... more trick to the amazing repertoire of carbon nanotubes ... cells. , Nanotubes, tiny hollow carbon filaments about one ... famed as one of the most versatile materials ever ... one-sixth as dense, able to conduct electricity better than ...
... mouse or a rat under stress and what does ... lucky. When people suffer nontraumatic stress they often head ... Syrian hamsters, which are normally solitary, are placed in ... at the Center for Behavioral Neuroscience at Georgia State ...
Cached Biology News:US infant mortality rate fails to improve 2Nanotubes used for first time to send signals to nerve cells 2Just like us, social stress prompts hamsters to overeat, gain weight 2Just like us, social stress prompts hamsters to overeat, gain weight 3Just like us, social stress prompts hamsters to overeat, gain weight 4
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
... 2 (VMAT2). An antibody made to the ... at ~55 kDa in postnuclear supernatants of ... wild type cells (2). Some additional bands, ... also detected and remain unaffected by the ...
... Anti-Matrix Metalloproteinase-2, Hinge Region By immunoblotting ... native protein. It reacts with free MMP-2 ... antibody buffered aqueous glycerol solution ... pH 7.4, containing 50% glycerol and 15 ...
Acetylcholinesterase from human and monkey....
Biology Products: